2020 年 46 巻 1 号 p. 22-30
We experienced a case, in which a hospital pharmacist and community pharmacist cooperated by utilizing the pharmacist outpatient service and telephone follow-up, and continued to intervene in medication management and side effect monitoring of the outpatient.
Case report: The male patient in his 70s, with thyroid carcinoma metastasized to lung after receiving total thyroidectomy, was treated with radioactive iodine. However, because the radioactive iodine had no effect, he was treated with lenvatinib. Afterward, as he continued with outpatient treatment, he experienced a rise in blood pressure and hand-foot syndrome induced by lenvatinib. Then, the hospital pharmacist suggested the addition of azilsartan and amlodipine, and consultation with dermatology, to his attending doctor in the pharmacist outpatient service, and the community pharmacist assessed the effect of supportive care. By sharing information on the condition of the patient with each other, there was an improvement in the side effects and treatment of lenvatinib was continued. Furthermore, since confirmation that the medicine had been taken was conducted numerous times through cooperation between the hospital pharmacist and community pharmacist, he could continue treatment, and there was almost 100% compliance with the dosing protocol.
When we treat patients with medicine that potentially has serious side effects, we need to continue monitoring the side effects. Especially, in outpatients, cooperation between the hospital pharmacist and community pharmacist enables the provision of safer and better medical care.
